About EXCIVA GmbH

The German company is developing a targeted drug rescue program focused on creating therapies for neuropsychiatric symptoms in Alzheimer's disease, specifically agitation and aggression. By conducting rigorous clinical trials and collaborating with experts, the company aims to enhance the quality of life for patients and alleviate caregiver distress.

```xml <problem> Alzheimer's disease often presents with neuropsychiatric symptoms such as agitation and aggression, which significantly reduce the quality of life for patients and cause distress for caregivers. Current treatment options are limited and often ineffective in managing these behavioral disturbances. </problem> <solution> This company is developing a targeted drug rescue program to create therapies specifically for neuropsychiatric symptoms, including agitation and aggression, associated with Alzheimer's disease. The company focuses on rigorous clinical trials to ensure the safety and efficacy of its treatments. By collaborating with experts and conducting cutting-edge research, the company aims to deliver first-in-class and best-in-class treatments to improve the quality of life for patients, reduce caregiver burden, and support patients' families. The ultimate goal is to transform dementia care by providing comprehensive relief from neuropsychiatric symptoms. </solution> <features> - Focus on developing therapies for agitation and aggression in Alzheimer's disease. - Rigorous clinical trials to ensure safety and efficacy. - Collaboration with experts in the field of dementia and neuropsychiatric disorders. - Targeted drug rescue program to identify and repurpose existing drugs. </features> <target_audience> The primary target audience includes individuals diagnosed with Alzheimer's disease experiencing neuropsychiatric symptoms, their caregivers, and their families. </target_audience> ```

What does EXCIVA GmbH do?

When was EXCIVA GmbH founded?

EXCIVA GmbH was founded in 2015.

How much funding has EXCIVA GmbH raised?

EXCIVA GmbH has raised $10.4M.

Who founded EXCIVA GmbH?

EXCIVA GmbH was founded by Francois Conquet.

Francois Conquet - CEO

Founded

2015

Funding

$10.4M

Employees

6 employees

Investors

Lbbwvc

EXCIVA GmbH

Founded 20156200+ followers5/10 TractionRelative Traction Score based on online presence metrics compared to companies in the same age group.

Updated 19 months ago

Funding

$10.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

Product

Problem

Alzheimer's disease often presents with neuropsychiatric symptoms such as agitation and aggression, which significantly reduce the quality of life for patients and cause distress for caregivers. Current treatment options are limited and often ineffective in managing these behavioral disturbances.

Solution

This company is developing a targeted drug rescue program to create therapies specifically for neuropsychiatric symptoms, including agitation and aggression, associated with Alzheimer's disease. The company focuses on rigorous clinical trials to ensure the safety and efficacy of its treatments. By collaborating with experts and conducting cutting-edge research, the company aims to deliver first-in-class and best-in-class treatments to improve the quality of life for patients, reduce caregiver burden, and support patients' families. The ultimate goal is to transform dementia care by providing comprehensive relief from neuropsychiatric symptoms.

Target Audience

The primary target audience includes individuals diagnosed with Alzheimer's disease experiencing neuropsychiatric symptoms, their caregivers, and their families.

Features

Focus on developing therapies for agitation and aggression in Alzheimer's disease.
Rigorous clinical trials to ensure safety and efficacy.
Collaboration with experts in the field of dementia and neuropsychiatric disorders.
Targeted drug rescue program to identify and repurpose existing drugs.